SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Julie Rousseau, Roberta Gioia, Pierre Layrolle, Blandine Lieubeau, Dominique Heymann, Antonio Rossi, Joan C Marini, Valerie Trichet, Antonella Forlino, Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta, European Journal of Human Genetics, 2014, 22, 5, 667

    CrossRef

  2. 2
    Laura K. Wood, Steven J. Langford, Motor Neuron Disease: A Chemical Perspective, Journal of Medicinal Chemistry, 2014, 57, 15, 6316

    CrossRef

  3. 3
    Lisa Gherardini, Giuseppe Bardi, Mariangela Gennaro, Tommaso Pizzorusso, Novel siRNA delivery strategy: a new “strand” in CNS translational medicine?, Cellular and Molecular Life Sciences, 2014, 71, 1, 1

    CrossRef

  4. 4
    H. Wang, B. Yang, L. Qiu, C. Yang, J. Kramer, Q. Su, Y. Guo, R. H. Brown, G. Gao, Z. Xu, Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis, Human Molecular Genetics, 2014, 23, 3, 668

    CrossRef

  5. 5
    Sidi Yang, Yufei Chen, Roien Ahmadie, Emmanuel A. Ho, Advancements in the field of intravaginal siRNA delivery, Journal of Controlled Release, 2013, 167, 1, 29

    CrossRef

  6. 6
    Troels Nielsen, Jørgen Nielsen, Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?, Genes, 2013, 4, 3, 457

    CrossRef

  7. 7
    Liang Meng Wee, C. Fabián Flores-Jasso, William E. Salomon, Phillip D. Zamore, Argonaute Divides Its RNA Guide into Domains with Distinct Functions and RNA-Binding Properties, Cell, 2012, 151, 5, 1055

    CrossRef

  8. 8
    Malgosia M Pakulska, Brian G Ballios, Molly S Shoichet, Injectable hydrogels for central nervous system therapy, Biomedical Materials, 2012, 7, 2, 024101

    CrossRef

  9. 9
    J Kaplan, F S Kaplan, E M Shore, Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting, Gene Therapy, 2012, 19, 7, 786

    CrossRef

  10. 10
    Robyn P Hickerson, Sancy A Leachman, Lana N Pho, Emilio Gonzalez-Gonzalez, Frances J D Smith, W H Irwin McLean, Christopher H Contag, Devin Leake, Leonard M Milstone, Roger L Kaspar, Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials, Journal of Investigative Dermatology, 2011, 131, 5, 1029

    CrossRef

  11. 11
    W. J. Bowers, X. O. Breakefield, M. Sena-Esteves, Genetic therapy for the nervous system, Human Molecular Genetics, 2011, 20, R1, R28

    CrossRef

  12. 12
    Ben Berkhout, Rogier W. Sanders, Molecular strategies to design an escape-proof antiviral therapy, Antiviral Research, 2011, 92, 1, 7

    CrossRef

  13. 13
    Attila A. Seyhan, RNAi: a potential new class of therapeutic for human genetic disease, Human Genetics, 2011, 130, 5, 583

    CrossRef

  14. 14
    Jian-Jiao Wang, Qing-Song Li, Yang Li, Yong-Ri Zheng, WITHDRAWN: Discrimination of Parkinson-associated LRRK2 alleles by introduction of a single nucleotide mismatch into siRNA, Neuroscience Letters, 2011,

    CrossRef

  15. 15
    Julia J.M. Eekels, Ben Berkhout, Cellular RNA Interference Mechanisms, 2011,

    CrossRef

  16. 16
    Ken Webb, Jeoung Lee, Mechanobiology Handbook, 2011,

    CrossRef

  17. 17
    Wei Cong, Shaoqiang Cui, Jiulian Chen, Xiaoping Zuo, Yonggan Lu, Weiyao Yan, Zhaoxin Zheng, Construction of a multiple targeting RNAi plasmid that inhibits target gene expression and FMDV replication in BHK-21 cells and suckling mice, Veterinary Research Communications, 2010, 34, 4, 335

    CrossRef

  18. 18
    Xu Teng, Wei-Zhen Xu, Mei-Li Hao, Yong Fang, Ying-Xin Zhao, Si-Jia Chen, Di Li, Hong-Xi Gu, Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi, Journal of Virological Methods, 2010, 168, 1-2, 6

    CrossRef

  19. 19
    Emilio Gonzalez-Gonzalez, Tycho J Speaker, Robyn P Hickerson, Ryan Spitler, Manuel A Flores, Devin Leake, Christopher H Contag, Roger L Kaspar, Silencing of Reporter Gene Expression in Skin Using siRNAs and Expression of Plasmid DNA Delivered by a Soluble Protrusion Array Device (PAD), Molecular Therapy, 2010, 18, 9, 1667

    CrossRef

  20. 20
    Janine Scholefield, Matthew J.A. Wood, Therapeutic gene silencing strategies for polyglutamine disorders, Trends in Genetics, 2010, 26, 1, 29

    CrossRef

  21. 21
    O R F Mook, F Baas, M B de Wissel, K Fluiter, Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A, Cancer Gene Therapy, 2009, 16, 6, 532

    CrossRef

  22. 22
    Edith L. Pfister, Lori Kennington, Juerg Straubhaar, Sujata Wagh, Wanzhou Liu, Marian DiFiglia, Bernhard Landwehrmeyer, Jean-Paul Vonsattel, Phillip D. Zamore, Neil Aronin, Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients, Current Biology, 2009, 19, 9, 774

    CrossRef

  23. 23
    Edith L. Pfister, Phillip D. Zamore, Huntington's disease: Silencing a brutal killer, Experimental Neurology, 2009, 220, 2, 226

    CrossRef

  24. 24
    Yu-Cheng Tseng, Subho Mozumdar, Leaf Huang, Lipid-based systemic delivery of siRNA, Advanced Drug Delivery Reviews, 2009, 61, 9, 721

    CrossRef

  25. 25
    Rui Wu, Hongyan Wang, Xugang Xia, Hongxia Zhou, Chunyan Liu, Maria Castro, Zuoshang Xu, Nerve Injection of Viral Vectors Efficiently Transfers Transgenes into Motor Neurons and Delivers RNAi Therapy Against ALS, Antioxidants & Redox Signaling, 2009, 11, 7, 1523

    CrossRef

  26. 26
    Megha Ghildiyal, Phillip D. Zamore, Small silencing RNAs: an expanding universe, Nature Reviews Genetics, 2009, 10, 2, 94

    CrossRef

  27. 27
    ROGER BERTOLOTTI, TRANSLATIONAL PERSPECTIVES — TRANSIENT EPIGENETIC GENE THERAPY: HAZARD-FREE CELL REPROGRAMMING APPROACH AND RISING ARM OF A UNIVERSAL STEM CELL GENE THERAPY PLATFORM, Gene Therapy and Regulation, 2009, 04, 01, 11

    CrossRef

  28. 28
    Michael S Hildebrand, Stephen S Newton, Samuel P Gubbels, Abraham M Sheffield, Amit Kochhar, Michelle G de Silva, Hans-Henrik M Dahl, Scott D Rose, Mark A Behlke, Richard JH Smith, Advances in Molecular and Cellular Therapies for Hearing Loss, Molecular Therapy, 2008, 16, 2, 224

    CrossRef

  29. 29
    Chang-ming GENG, Hong-liu DING, Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele, Acta Pharmacologica Sinica, 2008, 29, 2
  30. 30
    Jingqun Zhang, Honglei Sun, Yexin Ma, Daowen Wang, Effects of RNA interference targeting angiotensin 1a receptor on blood pressure and cardiac hypertrophy of rats with renovascular hypertension, Frontiers of Medicine in China, 2008, 2, 1, 19

    CrossRef

  31. 31
    P.H.J. van Bilsen, L. Jaspers, M.S. Lombardi, J.C.E. Odekerken, E.N. Burright, W.F. Kaemmerer, Identification and Allele-Specific Silencing of the Mutant Huntingtin Allele in Huntington's Disease Patient-Derived Fibroblasts, Human Gene Therapy, 2008, 19, 7, 710

    CrossRef

  32. 32
    Wanzhao Liu, Lori A Kennington, H Diana Rosas, Steven Hersch, Jang-Ho Cha, Phillip D Zamore, Neil Aronin, Linking SNPs to CAG repeat length in Huntington's disease patients, Nature Methods, 2008, 5, 11, 951

    CrossRef

  33. 33
    Meihong Chen, Quan Du, Hong-Yan Zhang, Xiaoxia Wang, Zicai Liang, High-throughput screening using siRNA (RNAi) libraries, Expert Review of Molecular Diagnostics, 2007, 7, 3, 281

    CrossRef

  34. 34
    Thais Federici, Nicholas M. Boulis, RIBONUCLEIC ACID INTERFERENCE FOR NEUROLOGICAL DISORDERS, Neurosurgery, 2007, 60, 1, 3???16

    CrossRef

  35. 35
    Lars Aagaard, John J. Rossi, RNAi therapeutics: Principles, prospects and challenges, Advanced Drug Delivery Reviews, 2007, 59, 2-3, 75

    CrossRef

  36. 36
    Robyn P Hickerson, Frances J D Smith, Robert E Reeves, Christopher H Contag, Devin Leake, Sancy A Leachman, Leonard M Milstone, W H Irwin McLean, Roger L Kaspar, Single-Nucleotide-Specific siRNA Targeting in a Dominant-Negative Skin Model, Journal of Investigative Dermatology, 2007,

    CrossRef

  37. 37
    A. L. C. Cardoso, S. Simões, L. P. de Almeida, J. Pelisek, C. Culmsee, E. Wagner, M. C. Pedroso de Lima, siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing, The Journal of Gene Medicine, 2007, 9, 3
  38. 38
    Pedro Gonzalez-Alegre, Therapeutic RNA interference for neurodegenerative diseases: From promise to progress, Pharmacology & Therapeutics, 2007, 114, 1, 34

    CrossRef

  39. 39
    M. DiFiglia, M. Sena-Esteves, K. Chase, E. Sapp, E. Pfister, M. Sass, J. Yoder, P. Reeves, R. K. Pandey, K. G. Rajeev, M. Manoharan, D. W. Y. Sah, P. D. Zamore, N. Aronin, Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits, Proceedings of the National Academy of Sciences, 2007, 104, 43, 17204

    CrossRef

  40. 40
    E Rodriguez-Lebron, H L Paulson, Allele-specific RNA interference for neurological disease, Gene Therapy, 2006, 13, 6, 576

    CrossRef

  41. 41
    Xugang Xia, Hongxia Zhou, Yong Huang, Zuoshang Xu, Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo, Neurobiology of Disease, 2006, 23, 3, 578

    CrossRef

  42. 42
    Xiaorong Feng, Ping Zhao, Yunxiu He, Zhiyi Zuo, Allele-specific silencing of Alzheimer's disease genes, Gene, 2006, 371, 1, 68

    CrossRef

  43. 43
    Constança Figueiredo, Axel Seltsam, Rainer Blasczyk, Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery, Journal of Molecular Medicine, 2006, 84, 5, 425

    CrossRef

  44. 44
    Dianne S. Schwarz, Hongliu Ding, Lori Kennington, Jessica T. Moore, Janell Schelter, Julja Burchard, Peter S. Linsley, Neil Aronin, Zuoshang Xu, Phillip D. Zamore, Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide, PLoS Genetics, 2006, 2, 9, e140

    CrossRef

  45. 45
    D. M. Dykxhoorn, L. D. Schlehuber, I. M. London, J. Lieberman, Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism, Proceedings of the National Academy of Sciences, 2006, 103, 15, 5953

    CrossRef

  46. 46
    Thais Federici, Nicholas M. Boulis, Gene-based treatment of motor neuron diseases, Muscle & Nerve, 2006, 33, 3
  47. 47
    Deepak R. Thakker, Daniel Hoyer, John F. Cryan, Interfering with the brain: Use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders, Pharmacology & Therapeutics, 2006, 109, 3, 413

    CrossRef

  48. 48
    Edgardo Rodriguez-Lebron, Pedro Gonzalez-Alegre, Silencing neurodegenerative disease: bringing RNA interference to the clinic, Expert Review of Neurotherapeutics, 2006, 6, 2, 223

    CrossRef

  49. 49
    S.H. Lee, P.J. Sinko, siRNA—Getting the message out, European Journal of Pharmaceutical Sciences, 2006, 27, 5, 401

    CrossRef

  50. 50
    N Aronin, Target selectivity in mRNA silencing, Gene Therapy, 2006, 13, 6, 509

    CrossRef

  51. 51
    Marina Ulanova, Alan D Schreiber, A Dean Befus, The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases, BioDrugs, 2006, 20, 1, 1

    CrossRef

  52. 52
    D M Dykxhoorn, D Palliser, J Lieberman, The silent treatment: siRNAs as small molecule drugs, Gene Therapy, 2006, 13, 6, 541

    CrossRef

  53. 53
    Lucie I Bruijn, Merit Cudkowicz, Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies, Expert Review of Neurotherapeutics, 2006, 6, 3, 417

    CrossRef

  54. 54
    C Raoul, S D Barker, P Aebischer, Viral-based modelling and correction of neurodegenerative diseases by RNA interference, Gene Therapy, 2006, 13, 6, 487

    CrossRef

  55. 55
    Xu Gang Xia, Hongxia Zhou, Sili Zhou, Yingping Yu, Rui Wu, Zuoshang Xu, An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase, Journal of Neurochemistry, 2005, 92, 2
  56. 56
    Vladimir Pekarik, Design of shRNAs for RNAi—A lesson from pre-miRNA processing: Possible clinical applications, Brain Research Bulletin, 2005, 68, 1-2, 115

    CrossRef

  57. 57
    Cédric Raoul, Toufik Abbas-Terki, Jean-Charles Bensadoun, Sandrine Guillot, Georg Haase, Jolanta Szulc, Christopher E Henderson, Patrick Aebischer, Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS, Nature Medicine, 2005, 11, 43, 423

    CrossRef

  58. You have free access to this content58
    Meenakshi Rao, Shanthini Sockanathan, Molecular mechanisms of RNAi: Implications for development and disease, Birth Defects Research Part C: Embryo Today: Reviews, 2005, 75, 1
  59. 59
    Juergen Hoelters, Marisa Ciccarella, Marei Drechsel, Claudia Geissler, Hülya Gülkan, Wolfgang Böcker, Matthias Schieker, Marianne Jochum, Peter Neth, Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells, The Journal of Gene Medicine, 2005, 7, 6
  60. 60
    Xu Gang Xia, Hongxia Zhou, Zuoshang Xu, Promises and Challenges in Developing RNAi as a Research Tool and Therapy for Neurodegenerative Diseases, Neurodegenerative Diseases, 2005, 2, 3-4, 220

    CrossRef

  61. 61
    Victor M. Miller, Henry L. Paulson, Pedro Gonzalez-Alegre, RNA Interference in Neuroscience: Progress and Challenges, Cellular and Molecular Neurobiology, 2005, 25, 8, 1195

    CrossRef

  62. 62
    Christopher P. Dillon, Peter Sandy, Alessio Nencioni, Stephan Kissler, Douglas A. Rubinson, Luk Van Parijs, RNAI AS AN EXPERIMENTAL AND THERAPEUTIC TOOL TO STUDY AND REGULATE PHYSIOLOGICAL AND DISEASE PROCESSES, Annual Review of Physiology, 2005, 67, 1, 147

    CrossRef

  63. 63
    Z Xu, X G Xia, RNAi therapy: Dominant disease gene gets silenced, Gene Therapy, 2005, 12, 15, 1159

    CrossRef

  64. 64
    Takayuki Kurosawa, Shuichi Igarashi, Masatoyo Nishizawa, Osamu Onodera, Selective silencing of a mutant transthyretin allele by small interfering RNAs, Biochemical and Biophysical Research Communications, 2005, 337, 3, 1012

    CrossRef

  65. 65
    G Scott Ralph, Pippa A Radcliffe, Denise M Day, Janine M Carthy, Marie A Leroux, Debbie C P Lee, Liang-Fong Wong, Lynsey G Bilsland, Linda Greensmith, Susan M Kingsman, Kyriacos A Mitrophanous, Nicholas D Mazarakis, Mimoun Azzouz, Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model, Nature Medicine, 2005, 11, 43, 429

    CrossRef

  66. 66
    Derek M. Dykxhoorn, Judy Lieberman, The Silent Revolution: RNA Interference as Basic Biology, Research Tool, and Therapeutic, Annual Review of Medicine, 2005, 56, 1, 401

    CrossRef

  67. 67
    Susan L. Uprichard, The therapeutic potential of RNA interference, FEBS Letters, 2005, 579, 26, 5996

    CrossRef

  68. 68
    Alison M. Gurney, Elaine Hunter, The use of small interfering RNA to elucidate the activity and function of ion channel genes in an intact tissue, Journal of Pharmacological and Toxicological Methods, 2005, 51, 3, 253

    CrossRef

  69. 69
    G. Scott Ralph, Nicholas D. Mazarakis, Mimoun Azzouz, Therapeutic gene silencing in neurological disorders, using interfering RNA, Journal of Molecular Medicine, 2005, 83, 6, 413

    CrossRef

  70. 70
    Timothy M. Miller, Brian K. Kaspar, Geert J. Kops, Koji Yamanaka, Lindsey J. Christian, Fred H. Gage, Don W. Cleveland, Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis, Annals of Neurology, 2005, 57, 5
  71. 71
    Benjamin Haley, Phillip D Zamore, Kinetic analysis of the RNAi enzyme complex, Nature Structural & Molecular Biology, 2004, 11, 7, 599

    CrossRef

  72. 72
    Caterina Bendotti, Maria Teresa Carrì, Lessons from models of SOD1-linked familial ALS, Trends in Molecular Medicine, 2004, 10, 8, 393

    CrossRef

  73. 73
    Allison C Mallory, Brenda J Reinhart, Matthew W Jones-Rhoades, Guiliang Tang, Phillip D Zamore, M Kathryn Barton, David P Bartel, MicroRNA control of PHABULOSA in leaf development: importance of pairing to the microRNA 5′ region, The EMBO Journal, 2004, 23, 16
  74. 74
    Beverly L Davidson, Henry L Paulson, Molecular medicine for the brain: silencing of disease genes with RNA interference, The Lancet Neurology, 2004, 3, 3, 145

    CrossRef

  75. 75
    M. M. Maxwell, P. Pasinelli, A. G. Kazantsev, R. H. Brown, RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells, Proceedings of the National Academy of Sciences, 2004, 101, 9, 3178

    CrossRef

  76. 76
    Stephan Geley, Christiane Müller, RNAi: ancient mechanism with a promising future, Experimental Gerontology, 2004, 39, 7, 985

    CrossRef

  77. 77
    Yair Dorsett, Thomas Tuschl, siRNAs: applications in functional genomics and potential as therapeutics, Nature Reviews Drug Discovery, 2004, 3, 4, 318

    CrossRef

  78. 78
    Joseph M Alisky, Beverly L Davidson, Towards Therapy Using RNA Interference, American Journal of PharmacoGenomics, 2004, 4, 1, 45

    CrossRef

  79. 79
    Gregory J. Hannon, John J. Rossi, Unlocking the potential of the human genome with RNA interference, Nature, 2004, 431, 7006, 371

    CrossRef

  80. 80
    Lucie I. Bruijn, Timothy M. Miller, Don W. Cleveland, UNRAVELING THE MECHANISMS INVOLVED IN MOTOR NEURON DEGENERATION IN ALS, Annual Review of Neuroscience, 2004, 27, 1, 723

    CrossRef

  81. 81
    Nathan R Wall, Yang Shi, Small RNA: can RNA interference be exploited for therapy?, The Lancet, 2003, 362, 9393, 1401

    CrossRef

  82. 82
    Karin J. von Eije, Ben Berkhout, Antiviral RNAi: How to Silence Viruses,
  83. 83
    Andrew V. Oleinikov, Matthew D. Gray, RNA Interference: The Next Gene-Targeted Medicine, Pharmaceutical Sciences Encyclopedia,
  84. 84
    Gregor P. Lotz, Paul J. Muchowski, Therapies Aimed at Controlling Gene Expression, Including up-Regulating a Chaperone or down-Regulating an Amyloidogenic Protein,